HRP20260301T1 - Formulacija implantata koja sadrži risperidon - Google Patents
Formulacija implantata koja sadrži risperidonInfo
- Publication number
- HRP20260301T1 HRP20260301T1 HRP20260301TT HRP20260301T HRP20260301T1 HR P20260301 T1 HRP20260301 T1 HR P20260301T1 HR P20260301T T HRP20260301T T HR P20260301TT HR P20260301 T HRP20260301 T HR P20260301T HR P20260301 T1 HRP20260301 T1 HR P20260301T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation containing
- implant formulation
- containing risperidone
- risperidone
- implant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170362.3A EP2529756B1 (en) | 2011-05-31 | 2012-05-31 | Risperidone and/or Paliperidone implant formulation |
| PCT/EP2013/061320 WO2013178812A1 (en) | 2012-05-31 | 2013-05-31 | Risperidone or paliperidone implant formulation |
| EP13726003.0A EP2854858B1 (en) | 2012-05-31 | 2013-05-31 | Risperidone implant formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20260301T1 true HRP20260301T1 (hr) | 2026-04-10 |
Family
ID=46147376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20260301TT HRP20260301T1 (hr) | 2012-05-31 | 2013-05-31 | Formulacija implantata koja sadrži risperidon |
| HRP20211057TT HRP20211057T1 (hr) | 2011-05-31 | 2021-07-02 | Formulacija implantata od risperidona i/ili paliperidona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211057TT HRP20211057T1 (hr) | 2011-05-31 | 2021-07-02 | Formulacija implantata od risperidona i/ili paliperidona |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP2529756B1 (https=) |
| JP (1) | JP6367795B2 (https=) |
| KR (1) | KR101880716B1 (https=) |
| CN (1) | CN104363923A (https=) |
| AU (1) | AU2013269547B2 (https=) |
| BR (1) | BR112014029209A2 (https=) |
| CA (1) | CA2874765C (https=) |
| CL (1) | CL2014003216A1 (https=) |
| CO (1) | CO7160108A2 (https=) |
| CY (1) | CY1124369T1 (https=) |
| DK (2) | DK2529756T3 (https=) |
| EA (1) | EA031819B1 (https=) |
| ES (1) | ES2878112T3 (https=) |
| FI (1) | FI2854858T3 (https=) |
| HR (2) | HRP20260301T1 (https=) |
| IL (1) | IL235849B (https=) |
| IN (1) | IN2014DN10672A (https=) |
| LT (2) | LT2529756T (https=) |
| MA (1) | MA37664B1 (https=) |
| MX (1) | MX374955B (https=) |
| MY (1) | MY174999A (https=) |
| NZ (1) | NZ703321A (https=) |
| PH (1) | PH12014502667B1 (https=) |
| PL (2) | PL2529756T3 (https=) |
| PT (2) | PT2529756T (https=) |
| RS (1) | RS62059B1 (https=) |
| SG (1) | SG11201407961WA (https=) |
| SI (1) | SI2529756T1 (https=) |
| SM (1) | SMT202100448T1 (https=) |
| UA (1) | UA119430C2 (https=) |
| WO (1) | WO2013178812A1 (https=) |
| ZA (1) | ZA201409299B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| LT2394664T (lt) | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| PT2394663T (pt) | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
| HK1220628A1 (zh) | 2013-03-11 | 2017-05-12 | Durect Corporation | 包含高粘度液体载体的可注射控制释放组合物 |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| CN104922085B (zh) * | 2015-06-01 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种利培酮植入剂及其制备方法 |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| AU2023281232A1 (en) | 2022-05-18 | 2024-10-24 | Laboratorios Farmacéuticos Rovi, S.A. | Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| WO2005007122A2 (en) * | 2003-07-18 | 2005-01-27 | Oakwood Laboratories, L.L.C. | Polymer stabilization |
| JP2008509144A (ja) | 2004-08-04 | 2008-03-27 | アルザ・コーポレーシヨン | 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法 |
| JP5315336B2 (ja) | 2007-04-19 | 2013-10-16 | 又欣 李 | 精神疾患治療用の新規化合物とその調剤及び使用 |
| DK2167039T3 (en) * | 2007-05-18 | 2017-01-09 | Durect Corp | Improved depot formulations |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| WO2009015828A1 (en) | 2007-07-27 | 2009-02-05 | Synthon B.V. | Paliperidone derivatives |
| BRPI0821408A2 (pt) | 2007-12-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação |
| EP2485712A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| LT2394664T (lt) | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| PT2394663T (pt) * | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
-
2012
- 2012-05-31 LT LTEP12170362.3T patent/LT2529756T/lt unknown
- 2012-05-31 SM SM20210448T patent/SMT202100448T1/it unknown
- 2012-05-31 DK DK12170362.3T patent/DK2529756T3/da active
- 2012-05-31 ES ES12170362T patent/ES2878112T3/es active Active
- 2012-05-31 EP EP12170362.3A patent/EP2529756B1/en active Active
- 2012-05-31 RS RS20210834A patent/RS62059B1/sr unknown
- 2012-05-31 PL PL12170362T patent/PL2529756T3/pl unknown
- 2012-05-31 SI SI201231933T patent/SI2529756T1/sl unknown
- 2012-05-31 PT PT121703623T patent/PT2529756T/pt unknown
-
2013
- 2013-05-31 CA CA2874765A patent/CA2874765C/en active Active
- 2013-05-31 BR BR112014029209A patent/BR112014029209A2/pt not_active Application Discontinuation
- 2013-05-31 DK DK13726003.0T patent/DK2854858T3/da active
- 2013-05-31 CN CN201380027927.8A patent/CN104363923A/zh active Pending
- 2013-05-31 WO PCT/EP2013/061320 patent/WO2013178812A1/en not_active Ceased
- 2013-05-31 SG SG11201407961WA patent/SG11201407961WA/en unknown
- 2013-05-31 MY MYPI2014703551A patent/MY174999A/en unknown
- 2013-05-31 KR KR1020147035300A patent/KR101880716B1/ko active Active
- 2013-05-31 JP JP2015514533A patent/JP6367795B2/ja active Active
- 2013-05-31 MX MX2014014483A patent/MX374955B/es active IP Right Grant
- 2013-05-31 HR HRP20260301TT patent/HRP20260301T1/hr unknown
- 2013-05-31 EP EP13726003.0A patent/EP2854858B1/en active Active
- 2013-05-31 AU AU2013269547A patent/AU2013269547B2/en active Active
- 2013-05-31 FI FIEP13726003.0T patent/FI2854858T3/fi active
- 2013-05-31 IN IN10672DEN2014 patent/IN2014DN10672A/en unknown
- 2013-05-31 PL PL13726003.0T patent/PL2854858T3/pl unknown
- 2013-05-31 NZ NZ703321A patent/NZ703321A/en unknown
- 2013-05-31 LT LTEPPCT/EP2013/061320T patent/LT2854858T/lt unknown
- 2013-05-31 UA UAA201414187A patent/UA119430C2/uk unknown
- 2013-05-31 EA EA201401346A patent/EA031819B1/ru unknown
- 2013-05-31 PT PT137260030T patent/PT2854858T/pt unknown
-
2014
- 2014-11-23 IL IL235849A patent/IL235849B/en active IP Right Grant
- 2014-11-26 CL CL2014003216A patent/CL2014003216A1/es unknown
- 2014-11-28 PH PH12014502667A patent/PH12014502667B1/en unknown
- 2014-12-16 MA MA37664A patent/MA37664B1/fr unknown
- 2014-12-17 ZA ZA2014/09299A patent/ZA201409299B/en unknown
- 2014-12-30 CO CO14285844A patent/CO7160108A2/es unknown
-
2021
- 2021-07-02 HR HRP20211057TT patent/HRP20211057T1/hr unknown
- 2021-07-16 CY CY20211100644T patent/CY1124369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20260301T1 (hr) | Formulacija implantata koja sadrži risperidon | |
| EP3818947C0 (en) | Fenestrated implant | |
| SMT201400044B (it) | Formulazione di impianto di paliperidone | |
| HRP20211423T4 (hr) | Formulacije enzalutamida | |
| IL236916B (en) | Implant encapsulation | |
| EP2887911A4 (en) | BAND DISC IMPLANT | |
| DK2668967T3 (da) | Implantat | |
| BR112014000015A2 (pt) | formulação | |
| DK2868318T4 (da) | Injicerbar formulering | |
| ZA201306000B (en) | Stable formulation | |
| ZA201409020B (en) | Pharmaceutical formulation | |
| DK2877155T3 (da) | Opioidformuleringer | |
| HUE045947T2 (hu) | Formuláció IBS kezelésére | |
| FR2995524B1 (fr) | Prothese endo-urinaire | |
| EP2770828A4 (en) | FORMULATION | |
| ZA201405925B (en) | Pharmaceutical formulation having improved stability | |
| PL2908835T3 (pl) | Stabilne formulacje | |
| EP2851085A4 (en) | STERILIZED COMPOSITION | |
| EP2773204A4 (en) | FORMULATION OF PAZOPANIB | |
| IL235111A0 (en) | Oral formulation | |
| DE102012022654A8 (de) | Dentales Implantat | |
| ES1076359Y (es) | Implante dental | |
| ZA201406407B (en) | Pharmaceutical formulation containing flupirtin | |
| PL2922571T3 (pl) | Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran | |
| ES2464418B1 (es) | Prótesis ortodóntica |